Israeli Study Finds Weight-Loss Injections Slow Small Bowel Capsule Transit Without Affecting Diagnostic Quality
A new Israeli study conducted at Assuta Medical Centers in Haifa and Raanana has found that GLP-1 receptor agonist medications, including Ozempic, Wegovy, and Mounjaro, significantly slow the transit time of video capsules through the small intestine by over an hour. The prospective, multicenter research involved 129 patients undergoing small bowel video capsule endoscopy, with 34 patients on GLP-1 drugs and 95 not receiving these treatments. The median capsule transit time in the small intestine was 311 minutes for the treated group compared to 236 minutes for others, a difference of approximately 75 minutes. After adjusting for factors such as age, BMI, diabetes status, and indication for the test, the delay remained independently associated with GLP-1 treatment, averaging an 83-minute longer transit time.
Despite the slower transit, the study found no statistically significant impact on the completion rate of the capsule examination, its quality, or the detection of clinically significant findings. Completion rates were 91.2% for patients on GLP-1 medications versus 98.9% for others, a difference not deemed statistically significant. There were also no significant differences in gastric transit time or bowel preparation quality between groups.
Dr. Rawee Hazan, head of the gastroenterology institute at Assuta Haifa and lead author, emphasized the importance of understanding these effects given the rising use of GLP-1 drugs for obesity and diabetes. He stated that the findings do not support routinely stopping these medications before capsule endoscopy but recommend individualized decisions based on patient characteristics. Nursing leaders Osnat Kalnitsky and Melachem Melachem highlighted the practical implications for clinical teams preparing patients on GLP-1 therapies for capsule endoscopy, suggesting tailored approaches that integrate medical and nursing considerations.
The study was published in the international journal BMJ Open Gastroenterology and provides new guidance on managing patients undergoing small bowel capsule endoscopy while on GLP-1 receptor agonist treatments.
